CORDIS
EU research results

CORDIS

English EN

European Training Network on (+)RNA Virus Replication and Antiviral Drug Development

Objective

Virus infections remain a major cause of disease, with dramatic costs in mortality, morbidity, and economic loss worldwide. There is an unmet need for potent antiviral drugs, in particular against viruses with a (+)RNA genome which include many important pathogens of humans and animals.

Antiviral drug development requires a detailed understanding of virus replication and effective translation of this knowledge into drug discovery. Europe needs well-trained experts with multidisciplinary skills to advance this field. However, few, if any, European training institutes have the broad know-how required to provide such a comprehensive training programme. The EUVIRNA partnership aims to fill this gap with the proposed EUVIRNA training programme.

The EUVIRNA partnership consists of six outstanding European academic partners and four industrial partners (one pharmaceutical R&D company and three SMEs), and an associated partner (SME specialized in education). All EUVIRNA partners are recognized leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary. Three Visiting Researchers will complement the expertise of the partners.

EUVIRNA aims to introduce 18 ESR’s and 2 ER’s to state-of-the-art knowledge and technology applied in molecular virology and antiviral therapy, with both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses to improve career development and perspectives. The industrial partners are actively involved in the entire programme, and will furthermore organize a 1-week industry-oriented conference aimed at further bridging the gap between academia and industry.

Thus, EUVIRNA offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in European molecular virology research and antiviral dru
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
3584 Cs Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 789 745

Administrative Contact

Frank Van Kuppeveld (Dr.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 615 738

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 496 083

Heidelberg University Hospital

Germany

EU Contribution

€ 454 774

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 458 069

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 525 745

JANSSEN INFECTIOUS DISEASES DIAGNOSTICS BVBA

Belgium

EU Contribution

€ 420 089

PIKE PHARMA GMBH

Switzerland

EU Contribution

€ 123 448

RIBOXX GMBH

Germany

EU Contribution

€ 447 329

ARATANA THERAPEUTICS NV

Belgium

EU Contribution

€ 420 089

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 224 985

UNIVERSITE DE LA MEDITERRANEE D'AIX-MARSEILLE II

France

Project information

Grant agreement ID: 264286

Status

Closed project

  • Start date

    1 March 2011

  • End date

    28 February 2015

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 4 976 094

  • EU contribution

    € 4 976 094

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands